Using ctDNA to Measure Treatment Effectiveness in Ovarian Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational clinical trial focuses on patients diagnosed with high-grade serous ovarian cancer who are receiving first-line maintenance treatment with PARP inhibitors following chemotherapy. The study involves collecting plasma samples at various stages, including before surgery, after chemotherapy, during maintenance therapy, and at disease progression, to analyze circulating tumor DNA (ctDNA) for specific genomic markers. The goal is to determine if ctDNA can predict the effectiveness of the treatment and facilitate early detection of disease recurrence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Ovarian cancer first diagnosed and treated;
2. Pathologically confirmed as epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer;
3. The stage of the disease is II-IV, and surgery will be performed after evaluation;
4. Age ≥ 18 years old;
5. Subjects and their families fully understand the research plan and sign an informed consent form.

Exclusion Criteria:

1. Pathologically confirmed as non-epithelial ovarian cancer;
2. Surgical treatment cannot be performed after evaluation;
3. Malignant tumors found in other parts of the study were found within five years before enrollment or at the time of enrollment;
4. Patients who do not agree to use clinical first-line targeted drugs;
5. Severe mental illness;
6. Severe cardiovascular disease, uncontrollable infection, or other uncontrollable comorbid diseases.

Where it's running

• Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
  Shanghai, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FRα expression in high-grade serous ovarian cancer (FRα positive)

  A retrospective study in Greece will test how often Folate Receptor Alpha is present in tumor samples from adults diagnosed with high-grade serous ovarian cancer.

  Recruiting Hellenic Cooperative Oncology Group · Athens · NCT07889843

• Routine shallow-coverage Whole Genome Sequencing of Cervical Smears to See if Ovarian Cancer is Found Earlier

  Researchers test whether analyzing DNA from cervical smears with shallow whole-genome sequencing can help detect high-grade serous ovarian cancer early in patients undergoing treatment for this cancer.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07821879

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

• Idetrexed plus olaparib for high-grade serous ovarian cancer

  This trial tests whether combining idetrexed and olaparib helps people with high-grade serous ovarian cancer that is resistant to standard treatments.

  Recruiting Phase 1 Institute of Cancer Research, United Kingdom · Cambridge, Cambridgeshire and 2 other locations · NCT06976892

• Investigating the Role of RPL8 Protein in Ovarian Cancer

  This study is trying to see if the RPL8 protein in ovarian cancer tumors can help doctors understand the disease better and make more informed treatment choices for patients.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, BO · NCT06777082

• Using liquid biopsies and breath samples to detect lung cancer mutations

  This study is testing if using samples from blood, sputum, and breath can help find lung cancer mutations in patients with non-small cell lung cancer before and after surgery.

  Recruiting St. Joseph's Healthcare Hamilton · Hamilton, Ontario · NCT06707519

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.